Should You Hold Myriad Genetics Stock in Your Portfolio Right Now?

Myriad Genetics (MYGN) is focused on oncology testing expansion and strategic collaborations, including AI-enabled diagnostics, to drive long-term growth, despite a 79% stock drop in the past year. UnitedHealthcare's decision to end GeneSight coverage and ongoing macroeconomic pressures pose significant revenue risks, evidenced by a 20% year-over-year decline in GeneSight revenues in Q1 2025 and a lowered 2025 earnings estimate. The company is also launching new tests, including Precise MRD, and has strong solvency with $92 million in cash and no short-term debt.

Analysis

Myriad Genetics (MYGN) is navigating a challenging period, marked by a significant 79% year-over-year stock price decline, despite strategic efforts to drive long-term growth in its core Oncology and Women's Health businesses. The company is advancing its product pipeline with innovations such as the AI-enabled diagnostic capabilities from its PATHOMIQ collaboration and the upcoming Precise MRD test, slated for a H1 2026 launch and supported by new patents. Positive operational momentum is evident in certain segments, with MyRisk testing volume in the affected population growing 11% year-over-year in Q1 2025 and prenatal testing revenues also increasing 11% year-over-year in the same period. Financially, Myriad maintains a strong solvency position, reporting $92 million in cash and cash equivalents with no short-term debt at the end of Q1 2025, and an earnings yield of 0.2% that notably surpasses the negative industry average; it also has a track record of surpassing earnings estimates, averaging a 210% surprise over the trailing four quarters. However, these strengths are counterbalanced by substantial headwinds. The termination of UnitedHealthcare's coverage for the GeneSight test, effective in the first half of 2025, has already resulted in a 20% year-over-year decline in GeneSight revenues in Q1. Compounding this, ongoing macroeconomic pressures, including inflation and potential U.S. tariffs, threaten profitability. Analyst sentiment reflects these concerns, with the Zacks Consensus Estimate for 2025 earnings recently revised downwards to 1 cent and 2025 revenues projected to fall by 3.1% year-over-year.

Key Decisions for Investors

• Investors should closely monitor Myriad's execution on its growth strategy, particularly the development and market reception of new products like Precise MRD and Precise Liquid, and the impact of strategic partnerships in offsetting revenue challenges such as the GeneSight coverage loss.
• A thorough risk-reward assessment is warranted, considering the substantial stock price depreciation against the company's innovation pipeline and strong solvency, weighed against the significant impact of the GeneSight revenue decline and persistent macroeconomic headwinds.
• Key indicators to watch include the company's ability to manage operating costs amidst inflationary pressures, navigate U.S. tariff impacts, and secure or expand payer coverage for its key diagnostic tests, all of which are critical for future financial performance and stock re-rating.